M30

M30 is a novel, multifunctional, brain-permeable small molecule drug that acts as an iron chelator and an irreversible inhibitor of both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). It is being developed for neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis. Its multimodal mechanism of action includes potent iron chelation, radical scavenging, and selective brain MAO inhibition, which leads to increased levels of dopamine, serotonin, and noradrenaline in the brain. M30 also upregulates neuroprotective-adaptive mechanisms, including hypoxia-inducible factor (HIF)-1α, various growth factors like vascular endothelial growth factor (VEGF), erythropoietin (EPO), brain-derived neurotrophic factor (BDNF), and glial cell-derived neurotrophic factor (GDNF), as well as antioxidant enzymes. Furthermore, it modulates pro-survival signaling pathways such as protein kinase C (PKC), mitogen-activated protein kinase (MAPK)/ERK kinase (MEK), protein kinase B (PKB/Akt), and glycogen synthase kinase-3β (GSK-3β). These actions contribute to its neuroprotective and neurorestorative properties, particularly in models of Parkinson's disease where it has shown to restore nigrostriatal dopamine neurons and increase dopamine levels.

Other names

5-(N-methyl-N-propargyaminomethyl)-8-hydroxyquinoline